What’s Coming Down The Pipeline: Drugs In Development For CAP
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
FDA Still Needs Convincing On Use Of Non-Inferiority Trials For CAP – Temple
Industry has provided little data supporting the use of non-inferiority trials as the basis for approval for community-acquired pneumonia, FDA Office of Medical Policy Director Bob Temple said at a recent workshop on clinical trial design for CAP
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011